Processa Pharmaceuticals
PCSA
7 hedge funds and large institutions have $66.5K invested in Processa Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 1 closing their positions.
0% more funds holding
Funds holding: 7 → 7 (0)
0% less ownership
Funds ownership: 0.06% → 0.06% (-0%)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
34% less capital invested
Capital invested by funds: $101K → $66.5K (-$34.5K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$3.88K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.02K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$822 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MSG
Main Street Group
Glen Allen,
Virginia
|
-$209 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Vanguard Group
Malvern,
Pennsylvania
| $33.5K | – | – | – |
|
|
2
Geode Capital Management
Boston,
Massachusetts
| $27K | +$3.88K | +99 | +14% |
|
|
TRCT
3
Tower Research Capital (TRC)
New York
| $4.99K | +$1.02K | +26 | +22% |
|
|
4
UBS Group
Zurich,
Switzerland
| $714 | +$822 | +21 | New |
|
5
Wells Fargo
San Francisco,
California
| $211 | – | – | – |
|
|
AF
6
Allworth Financial
Folsom,
California
| $117 | – | – | – |
|
7
Bank of America
Charlotte,
North Carolina
| $33 | – | – | – |
|
|
MIM
8
Macroview Investment Management
Bethesda,
Maryland
| $2 | – | – | – |
|
|
MSG
9
Main Street Group
Glen Allen,
Virginia
| – | -$209 | -4 | Closed |
|
PCSA Hedge Fund Activity: Q3 2024 in Review
7 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Processa Pharmaceuticals (PCSA) for Q3 2024, worth a combined $66.5K — down 34% from $101K a quarter earlier.
Fund positioning in PCSA was balanced in Q3 2024: 1 fund opened new positions, 1 closed out, 2 added to existing stakes and 0 trimmed.
The largest buyer was Geode Capital Management, adding an estimated $3.88K. The largest seller was Main Street Group, exiting entirely with an estimated $209 sold.
- 7 institutional investors held Processa Pharmaceuticals (PCSA) as of Q3 2024, unchanged from Q2 2024.
- Funds reported $66.5K of Processa Pharmaceuticals stock for Q3 2024, down 34% quarter-over-quarter.
- 1 fund opened new Processa Pharmaceuticals positions in Q3 2024 and 1 closed out, a net change of 0 holders.
- The largest Processa Pharmaceuticals buyer in Q3 2024 was Geode Capital Management, an estimated $3.88K added.
- The largest Processa Pharmaceuticals seller in Q3 2024 was Main Street Group, an estimated $209 sold.
Based on aggregated 13F filings for Q3 2024.